HAPILA extends co-operation with Transo-Pharm to meet Estriol demand

Gera, Germany: – High-potency active ingredient specialist HAPILA GmbH (HAPILA) is deepening its co-operation with fully licensed and certified international distribution and logistics specialist Transo-Pharm Handels-GmbH to meet increasing demand for the innovative API Estriol.

The partners will jointly expand the production and handling capacities at the HAPILA site in Gera that manufactures Estriol Micronized (CEP no.: R1-CEP 2013-277-Rev 00). Planning for the construction and installation work is well advanced and the new facility is expected to be completed during this year.

Combined competencies

HAPILA has been co-operating with Transo-Pharm since 2014 and together the alliance has succeeded in reaching increasing numbers of customers for API Estriol.

The co-operation is based on synergistic core competencies, matching HAPILA’s expertise in development of chemical synthesis and regulatory compliant GMP-compliant manufacturing of active pharmaceutical ingredients, with Transo-Pharm’s mastery of international marketing, development and sales, along with logistics (including GMP-compliant storage and shipping).

Shaping the future

“What started off as a strategic alliance has emerged over the years to a trusting partnership, in which we have successfully combined our respective core strengths for the benefit of our customers,” commented HAPILA CEO Dr. Uwe Müller.

“This is an essential reason for us not only to shape the present together – but especially the future,” said Dr. Müller.

About HAPILA GmbH

HAPILA GmbH is a Contract developer and manufacturer (CDMO) that provides high-value services to pharma, biotech and fine chemicals client companies in the development and cGMP manufacture of active pharmaceutical ingredients (APIs).

HAPILA is an independent company with particular experience in GMP-related development and GMP manufacturing, offering full regulated service for API (IMPD, ASMF) to very high scientific and quality assurance (QA) levels.

It supports the development and manufacture of drug products with patented processes and in-depth experience in the API value-creation chain from synthesis through purification to particle design.

The company’s mission is to supply exclusive products of highest quality, potency and safety in compliance with GMP and environmental protection guidelines. All HAPILA teamwork is focused on product quality and customer satisfaction.

All HAPILA chemical synthesis is carried out at in-house at its GMP certified laboratories at Gera, Thuringia, in east-central Germany.

When combined with purification and particle design, HAPILA’s chemical synthesis services cover the complete API value-creation chain, enabling it to be a highly efficient bridge-builder between API production and pharmaceutical end-use.

For more information, visit: https://www.hapila.de/en

About Transo-Pharm Handels-GmbH

Founded in 1987 and based in Germany, Transo-Pharm Handels-GmbH (Transo-Pharm) has established a global reputation as a trusted supplier of active pharmaceutical ingredients (APIs).

Via its head office in Siek, Schleswig-Holstein, and regional offices in Asia, USA and India, Transo-Pharm connects suppliers, customers and markets through communication, marketing expertise and mastery of logistics.

The company has achieved sustainable growth through long term partnerships and ability to deliver flexible, authentic and qualified solutions for pharmaceutical applications.

Transo-Pharm’s expertise for APIs has been developed in close cooperation with the pharmaceutical industry. Professional skills allow the company to provide a customized and complete regulatory support in the areas of qualification of manufactured APIs, GMP consulting and DMF establishment.

Learn more at: https://www.transopharm.com

Resources

Click on Transo-Pharm and HAPILA expand cooperation to view original announcement.
Click on HAPILA planning for new GMP production facilities for further information.